TY - JOUR
T1 - Disparities in the Use of Programmed Death 1 Immune Checkpoint Inhibitors
AU - O'Connor, Jeremy M.
AU - Seidl-Rathkopf, Kathi
AU - Torres, Aracelis Z.
AU - You, Paul
AU - Carson, Kenneth R.
AU - Ross, Joseph S.
AU - Gross, Cary P.
N1 - Funding Information:
We thank Emily Yin, Carolyn Presley, Anne Chiang, Kristen Fessele, Nate Nussbaum, Kerin Adelson, Katie Darius, and Amy Abernethy for their contributions to earlier iterations of this work. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official view of the NIH. This work was made possible by grant TL1 TR001864 from the National Center for Advancing Translational Science, a component of the NIH, as well as the Yale Center for Clinical Investigation at the Yale University School of Medicine. The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Publisher Copyright:
© AlphaMed Press 2018
PY - 2018/11
Y1 - 2018/11
N2 - Amid growing excitement for immune checkpoint inhibitors of programmed death protein 1 (anti-PD1 agents), little is known about whether race- or sex-based disparities exist in their use. In this observational study, we constructed a large and mostly community-based cohort of patients with advanced stage cancers, including melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma, to compare the odds of receiving systemic treatment with or without anti-PD1 agents by race and by sex. In multivariable models that adjusted for age, stage, and number of prior anticancer therapies, we found no significant race-based disparities in anti-PD1 treatment. However, among patients with NSCLC, males had significantly higher odds of receiving anti-PD1 treatment compared with females (odds ratio 1.13, 95% confidence interval 1.02–1.24, p =.02). This finding suggests that as anti-PD1 agents enter the market to transform patient care, it will be critical to monitor for disparities in the use of these drugs.
AB - Amid growing excitement for immune checkpoint inhibitors of programmed death protein 1 (anti-PD1 agents), little is known about whether race- or sex-based disparities exist in their use. In this observational study, we constructed a large and mostly community-based cohort of patients with advanced stage cancers, including melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma, to compare the odds of receiving systemic treatment with or without anti-PD1 agents by race and by sex. In multivariable models that adjusted for age, stage, and number of prior anticancer therapies, we found no significant race-based disparities in anti-PD1 treatment. However, among patients with NSCLC, males had significantly higher odds of receiving anti-PD1 treatment compared with females (odds ratio 1.13, 95% confidence interval 1.02–1.24, p =.02). This finding suggests that as anti-PD1 agents enter the market to transform patient care, it will be critical to monitor for disparities in the use of these drugs.
UR - http://www.scopus.com/inward/record.url?scp=85050920046&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050920046&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.2017-0673
DO - 10.1634/theoncologist.2017-0673
M3 - Article
C2 - 30012876
AN - SCOPUS:85050920046
SN - 1083-7159
VL - 23
SP - 1388
EP - 1390
JO - Oncologist
JF - Oncologist
IS - 11
ER -
